These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 35535633)
1. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab. Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633 [TBL] [Abstract][Full Text] [Related]
2. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K; J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683 [TBL] [Abstract][Full Text] [Related]
3. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670 [TBL] [Abstract][Full Text] [Related]
4. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925 [TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK. O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671 [TBL] [Abstract][Full Text] [Related]
8. Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study. Cristaudo A; Pigliacelli F; Sperati F; Orsini D; Cameli N; Morrone A; Mariano M Skin Res Technol; 2021 Sep; 27(5):810-813. PubMed ID: 33651467 [TBL] [Abstract][Full Text] [Related]
9. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163 [TBL] [Abstract][Full Text] [Related]
10. Facial atopic dermatitis may be exacerbated by masks: insights from a multicenter, teledermatology, prospective study during COVID-19 pandemic. Damiani G; Finelli R; Kridin K; Pacifico A; Bragazzi NL; Malagoli P; Fabbrocini G; Marasca C; Annunziata M; Grada A; Santus P; Savoia P; Gironi LC; Buja A; Linder D; Pigatto PD; Ital J Dermatol Venerol; 2022 Dec; 157(6):505-509. PubMed ID: 36177781 [TBL] [Abstract][Full Text] [Related]
11. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24. Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults. Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice. Matsutani M; Imai Y; Inoue Y; Nakatani-Kusakabe M; Natsuaki M; Yamanishi K; Kanazawa N J Dermatol; 2021 Oct; 48(10):1564-1568. PubMed ID: 34155694 [TBL] [Abstract][Full Text] [Related]
14. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G; J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697 [TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study. Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study. Zhou X; Yang G; Chen X; Zhang L Drugs Aging; 2023 Oct; 40(10):933-940. PubMed ID: 37610613 [TBL] [Abstract][Full Text] [Related]
17. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499 [TBL] [Abstract][Full Text] [Related]
18. Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients. Rovati C; Rossi M; Gelmetti A; Tomasi C; Calzavara-Pinton I; Venturini M; Calzavara-Pinton P; Arisi M Eur J Dermatol; 2021 Dec; 31(6):736-740. PubMed ID: 34704942 [TBL] [Abstract][Full Text] [Related]
19. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective. Chia SY; Wee LWY; Koh MJA Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751 [TBL] [Abstract][Full Text] [Related]
20. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. Ureña-Paniego C; Montero-Vílchez T; Sanabria-de-la-Torre R; Soto-Moreno A; Molina-Leyva A; Arias-Santiago S Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]